VBLT - VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting | Benzinga
Approved Merger with Notable Labs and All Other Proposals
Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions
MODI'IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT) ("VBL"), today announced that its shareholders voted to approve the previously announced proposed merger (the "Merger") with Notable Labs, Inc. ("Notable"), at the annual and special meeting (the "Meeting") which took place today, October 12, 2023.
Over 98% of the votes cast at the Meeting were cast in favor of the approval of the Merger. VBL's shareholders also voted to approve all other proposals presented at the Meeting, each of which are described in more detail in VBL's joint proxy statement/prospectus/information statement as filed with the U.S. Securities and Exchange Commission ("SEC") on September 5, 2023 and as supplemented on September 18, 2023 and on October 2, 2023.
The Merger is expected to close on or around October 16, 2023. After completion of the Merger, VBL will be renamed "Notable Labs, Ltd." and is expected to trade on The Nasdaq Capital Market under the symbol "NTBL" on or around October 17, 2023.
About VBL Therapeutics
Vascular Biogenics Ltd., operating as VBL Therapeutics (NASDAQ:VBLT), is a biopharmaceutical company that has historically focused on developing targeted therapies for cancer and immune-inflammatory diseases.
About Notable Labs, Inc.
Notable Labs, Inc., is ...